Duloxetine News and Research

RSS

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults aged 18 years and older. Duloxetine is not approved for use in pediatric patients.

Increasing the dosage of antidepressants does not carry benefits, analysis reveals

In the current issue of Psychotherapy and Psychosomatics a new analysis discloses that increasing the dosage of antidepressant drugs does not carry benefits. As many patients with unipolar depression do not respond sufficiently to initial antidepressant monotherapy, a dose increase of the current administered antidepressant (dose escalation, high-dose treatment) is frequently carried out as next treatment measure.

24 Oct 2017

Antidepressants used for chronic pain relief come with significant side effects

Chronic pain negatively impacts a person's quality of life. Often, over the counter pain medication, such as ibuprofen or aspirin, are ineffective in alleviating chronic pain. In these instances, a surprising choice is often a drug used to treat an entirely different condition - depression.

5 Sep 2017

Antidepressants and anti-seizure drugs can effectively treat diabetic nerve pain, research finds

A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain.

25 Mar 2017

Study reports presence of structural changes in the brain during medication treatment for depression

A study led by Ravi Bansal, PhD, and Bradley S. Peterson, MD, of The Saban Research Institute of Children's Hospital Los Angeles, has found structural differences in the cerebral cortex of patients with depression and that these differences normalize with appropriate medication.

7 Mar 2017

New position statement offers recommendations for physicians on prevention of diabetic neuropathy

An estimated 60 to 70 percent of people with diabetes develop some form of diabetic neuropathy, or the chronic nerve damage diabetes causes, according to the National Institute of Diabetes and Digestive and Kidney Diseases.

31 Jan 2017

Functional MRI brain scan may help predict patient’s response to antidepressant therapy

A functional MRI brain scan may help predict which patients will respond positively to antidepressant therapy, according to a new study published in the journal Brain.

25 Jan 2017

Depression drug can alleviate joint pain in postmenopausal women treated for breast cancer

A drug typically used to treat depression and anxiety can significantly reduce joint pain in postmenopausal women being treated for early stage breast cancer, according to new SWOG research to be presented Friday at a special plenary presentation at the San Antonio Breast Cancer Symposium.

9 Dec 2016

Combination approach could be more effective to treat fibromyalgia pain

Queen's University researcher Ian Gilron has uncovered a more effective way of treating fibromyalgia, a medical condition characterized by chronic widespread pain typically accompanied by fatigue, as well as sleep, mood and memory problems.

14 Jul 2016

Most antidepressants are ineffective at treating children and teens, study shows

The majority of antidepressants prescribed to treat children and teenagers with major depression are ineffective and may even be unsafe, warn researchers.

9 Jun 2016

Nutritional supplements can enhance effectiveness of antidepressants

An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.

26 Apr 2016

Botulinum toxin A injections combat neuropathic pain

Botulinum toxin A injections have a sustained beneficial effect in patients with neuropathic pain, shows a randomised trial.

3 Mar 2016

Unmet medication need in neuropathic pain

A systematic review and meta-analysis reveals that current treatments for neuropathic pain achieve only a moderate response in patients.

16 Jan 2015

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical announced today that it has launched a $2 million campaign on Crowdfunder.com to support further company clinical trials and FDA applications.

31 Dec 2014

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules.

12 Jun 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.

3 Apr 2014

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Patients with fibromyalgia syndrome (FMS) typically have widespread chronic pain and fatigue. For those with low vitamin D levels, vitamin D supplements can reduce pain and may be a cost-effective alternative or adjunct to other treatment, say researchers in the January 2014 issue of PAIN-.

17 Jan 2014

IQWiG completes first health economic evaluation

The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results.

31 Oct 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA.

3 Apr 2013